Iranian biotech company develops recombinant biologic drugs for skin regeneration
An Iranian knowledge-based company has developed a new line of recombinant biologic drugs for skin repair and regeneration using natural compounds such as edible mushrooms, Spirulina algae, and human blood serum.
According to the Iranian Vice Presidency for Science, Technology, and Knowledge-Based Economy, these innovative biologics are designed to treat a wide range of skin conditions, from chronic wounds and diabetic ulcers to pigmentation disorders and skin aging.
The company’s CEO, Maria Beihaghi, noted that the formulas are free from synthetic chemicals and do not cause allergic reactions, making them safe and effective for widespread medical use.
The production process incorporates natural delivery systems derived from Shiitake mushrooms, Spirulina, and human serum, enhancing skin healing without harmful side effects. Additionally, medicinal plant extracts have been added to reduce melanin production and combat free radicals, contributing to skin brightening and anti-aging effects.
These biologics are not only medically effective but also cost-efficient, helping to make advanced skin treatments more accessible to the general public.
The company sees broad applications for its products in treating eczema, hyperpigmentation, skin laxity, and more, promising a new chapter in natural, regenerative dermatology.
